Lundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisition

The USD 11.6bn acquisition bid for migraine firm Biohaven Pharmaceuticals would make Pfizer a direct competitor to Lundbeck. Even so, ”the migraine market is so big and so unsatisfied that there is room for multiple therapies,” says CEO Deborah Dunsire.

Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH

Lundbeck’s sales performance within its strategic brands was strong in the year’s first quarter, during which three out four of the firm’s key drugs beat analysts’ expectations.

That leaves one, not insignificant, disappointment for onlookers – Vyepti, Lundbeck’s newest drug targeting the migraine treatment market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs